1 / 32

Tilskuddsparadiset USA: Erfaringer med bruk av tilskudd i klinisk praksis sammenlignet med Norge

Join Oddveig Myhre, a Naturopathic Medical Doctor, as she shares her experiences with the use of intravenous nutritional therapy in clinical practice. Discover the benefits, applications, and research behind this innovative treatment approach.

bauerj
Download Presentation

Tilskuddsparadiset USA: Erfaringer med bruk av tilskudd i klinisk praksis sammenlignet med Norge

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Tilskuddsparadiset USA:Erfaringer med bruk av tilskudd i klinisk praksis sammenlignet med Norge Vitamindagene, Sandvika 23.mars, 2019 Oddveig Myhre, Naturterapeut (Norge) Naturopathic Medical Doctor (USA), MS Neuroimmunology, MA Food Studies (USA)

  2. Min utdannelse og erfaring • 1997: San Diego State University: BS Microbiology • 2002: Arizona State University: Masters of Science Microbiology/Neuroimmunology • 2005: Southwest College of Naturopathic Medicine and Health Sciences: Naturopathic Medical Doctor (NMD / ND) • Lege i USA med egen praksis (Phoenix Naturopathic Center i Scottsdale, AZ) • Lisens nr: 06935 • National Provider ID: 1386761443 • Skrevet 3 skolebøker for naturmedisin (med 2 kollegaer) • 2014: Chatham University, Pittsburgh: MA in Food Studies • Flyttet tilbake til Norge • Mars 2016 – Godkjent som Naturterapeut • Jobber hos Optimalhelse Senter Skien – OSS – som Naturterapeut. • www.velkommentiloss.no

  3. Part I: Del 1: 5 deler – 4.5 timer Del 2: praktisk eksam Part II (embedseksamen): Går over 5 dager Del 1: Biomedical Science: 2 deler, hver på 2.5 timer Del 2: CoreClinical Science: 3 deler over 3 d, 3.5 t hver Del 3: ClinicalElectives: 3 deler, 1.5 time hver

  4. www.scnm.edu

  5. Forskningskilder • Kilder: • US National Library of Medicine/ National Institutes of Health – PUBMED • PMID: 28682528 • Google Scholar • Referanser/Kilder oppgitt

  6. Intravenøs ernæringsbehandling • Ernæring administrert rett inn i blodårer enten som et push (direkte fra sprøyte) eller fra bag (sterilt vann/Ringers/0.9% NaCl) • Premisser: • Når oral behandling ikke fungerer • Mye brukt med fordøyelsesproblemer • Når behandlingsdosen er høyere enn hva fordøyelsen tåler • Pasienten skal sjekkes for: • Serum chemistry profile with electrolytes (metabolisk panel/BMP) • Complete blood count (CBC) with differential • Complete urinalysis • Weight

  7. Mest vanlige og populære intravenøse ernæringsbehandlinger • GlutathioneIV • Grå stær, grønn stær, alkoholisme, astma, kreft, hjerte og karsykdommer, høyt kolesterol, AIDs, ME, Alzheimers, osteoartrose, Parkinson’s, diabetes, COPD/KOLS, allergier, IBS, Crohn’sog redusert lever funksjon. • Alpha Lipoic Acid IV • diabetes, diabetes neuropathy, lever sykdommer, slag og andre nevrologiske sykdommer • ChelationIV • Calcium EDTA/disodiumEDTA – fjerner tungmetaller i kroppen (bly, kvikksølv), øker blodsirkulasjonen, høyt blodtrykk, CVD, demens, autisme, diabetes med mer

  8. Mest vanlige og populære IV behandlinger • Rapid Mineral Replacement (RMR) IV • Øker mineraler og elektrolytter i kroppen – øker energi, ME, stress relaterte problemer, utmattelse, generell følelse av tretthet • Magnesium IV • Atrial eller ventrikulær arrhythmia (som resultat av hjerteinfarkt), astma, KOLS, nervesmerter, hypertensjon, PVCs, tretthet, fibromyalgi, ME og hjerte og karsykdommer • High-dose Vitamin CIV • For immunforsvaret, mot kreft, motvirke bivirkningene av cellegift og stråle behandling. • Brukes av Cancer Treatment Center of America hvor MD, DO og NMD jobber sammen

  9. Høye doser av Vitamin C • For immunforsvaret • Ekstra tester: • Red blood cell G6PD (must be normal) • Glucose 6 phosphate dehydrogenase deficiency • Hemachromatose [1] Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH, Jr.: Phase I clinical trial of i.v. ascorbic acid in advancedmalignancy. Ann Oncol 2008, 19:1969-1974. [2] Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M: Pharmacologicascorbic acid concentrationsselectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. ProcNatlAcadSci U S A 2005, 20;102:13604-13609. [3] Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q: Pharmacologicascorbatesynergizeswithgemcitabine in preclinicalmodels of pancreatic cancer. Free RadicBiol Med 2011, 50:1610-1619. [4] Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M: Phase I evaluation of intravenousascorbic Acid in combination withgemcitabine and erlotinib in patientswithmetastaticpancreatic cancer. PLoS One 2012, 7:e29794.

  10. Forskning • Mayland, C., Bennett, M. & Allan, K., 2005. Vitamin C deficiency in cancer patients. Palliat Med, Volume 19, pp. 17-20. • McCormick, W., 1959. Cancer: a collagen disease, secondary to nutrition deficiency. Arch. Pediatr., Volume 76, pp. 166-171. • Mikirova, N., Casciari, J. & Riordan, N., 2012. Ascorbateinhibition of angiogenesis in aortic rings ex vivo and subcutaneousMatrigelplugs in vivo. J Angiogenesis Res, Volume 2, pp. 2-6. • Mikirova, N., Casciari, J., Taylor, P. & Rogers, A., 2012. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Trans Med, Volume 10, pp. 189-99. • Mikirova, N., Ichim, T. & Riordan, N., 2008. Anti-angiogenic effect of high doses of ascorbic acid.. J Transl Med, Volume 6, p. 50. • Mikirova, N., Rogers, A., Casciari, J. & Taylor, P., 2012. Effects of high dose intravenousascorbic acid onthelevel of inflammation in patientswithrheumatoidarthritis. Mod Res Inflamm, Volume 1, pp. 26-32. • Moertel, C. et al., 1985. High-dose vitamin C versus placebo in the treatment of patientswithadvanced cancer who have no prior chemotherapy: a randomized double-blind comparison.. NEJM, Volume 312, pp. 137-41. • Monti, D. et al., 2012. Phase I evaluation of intravenousascorbic acid in combination withgemcitabine and erlotinib in patientswithmetastaticpancreatic cancer. PLoS One, Volume 7, p. e29794. • Murata, A., Morishige, F. & Yamaguchi, H., 1982. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Res Suppl, Volume 23, pp. 103-13. • Okunieff, P. & Suit, H., 1987. Toxicity, radiationsensitivitymodification, and combineddrugeffects of ascorbic acid withmisonidazole in vivo onFSaIImurinefirbosarcomas. JNCI, Volume 79, pp. 377-81. • Padayatti, S. et al., 2006. Intravenous vitamin C as a cancer therapy: three cases. CMAJ, Volume 174, pp. 937-42. • Padayatty, S. & Levine, M., 2000. Reevaluation of ascorbate in cancer treatment: emergingevidence, openminds and serendipity. J Am Coll Nutr., Volume 19, pp. 423-5. • Padayatty, S. et al., 2010. Vitamin C: intravenous use by complementary and alternative medical practitioners and adverseeffects. PLoS ONE, Volume 5, p. 11414. • Padayatty, S. et al., 2004. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med., Volume 140, pp. 533-37. • Page, E. et al., 2007. Hypoxiaincudible factor-1 (alpha) stabilization in nonhypoxicconditions: role of oxidation and intracellualrascorbatedepletion. Mol Biol Cell, Volume 19, pp. 86-94. • Pollard, H., Levine, M., Eidelman, O. & Pollard, M., 2010. Pharmacologicalascorbic acid supressessyngenic tumor growth and metastases in hormone-refractory prostate cancer. In VIvo, Volume 2012, pp. 249-55. • Raloff, J., 2000. Antioxidantsmayhelp cancers thrive. Science News, Volume 157, p. 5. • Riordan, H. et al., 2005. A pilot clinicalstudy of continuousintravenousascorbate in terminal cancer patients. PR Health Sci J, Volume 24, pp. 269-76. • Riordan, H. et al., 2003. Intravenousascorbic acid: protocol for itsapplication and use. PR Health Sci. J., Volume 22, pp. 225-32. • Riordan, H., Jackson, J., Riordan, N. & Schultz, M., 1998. High-dose intravenous vitamin C in the treatment of a patient with renal cellcarcinoma of thekidney. J Ortho Med, Volume 13, pp. 72-3. • Riordan, N., JA, J. & Riordan, H., 1996. Intravenous vitamin C in a terminal cancer patient. J Ortho Med, Volume 11, pp. 80-2. • Riordan, N., Roirdan, H. & Meng, X., 1995. Intravenousascorbate as a tumor cytotoxicchemotherapeutic agent. Med Hypotheses, Volume 44, pp. 207-13. • Rivers, J., 1987. Safety of high-level vitamin C ingestion. In: Third Conference onAscorbic Acid. Ann NY AcadSci, Volume 489, pp. 95-102. • Shinozaki, K. et al., 2011. Ascorbic acid enhancesradiation-inducedapoptosis in an HL60 human leukemiacell line. J Ratiat Res, Volume 52, pp. 229-37. • Simone, C., Simone, N. S. V. & CB, S., 2007. Antioxidants and other nutrients do not inferferewithchemotherapy or radiation therapy and can increase survival, part 1. AtlernTher Health Med, Volume 13, pp. 22-8. • St. Sauver, J. et al., 2009. Associations betweeen c-reactive protein and benighprosaichyperplasialowerurinarytractoutcomes in a populationbasedcohort. Am J Epidemiol, Volume 169, pp. 1281-90. • Taper, H., Keyeux, A. & Roberfroid, M., 1996. Potentiation of radiotherapy by nontoxicpretreatmentwithcombined vitamins C and K3 in micebearing solid transplantable tumor. Anticancer Res, Volume 16, pp. 499-503. • Verrax, J. et al., 2004. Ascorbatepotentiatesthecytotoxicity of menadioneleading to an oxidative stress that kills cancer cells by a non-apoptotic capsase-3 independent form of celldeath. Apoptosis, Volume 9, pp. 223-33. • Verrax, J. & Calderon, P., 2009. Pharmacologicconcentrations of ascorbateareachieved by parenteral administration and exhibitantitumoraleffects. Free RadicBiol Med, Volume 47, pp. 32-40. • Vollbracht, C. et al., 2011. Intravenous vitamin C administrationimprovesquality of life in breastcacnerpatients during chemo-radiotherapy and aftercare: results of a retrospective, multicentre, epidemiologicalcohortstudy in Germany. In Vivo, Volume 82, pp. 983-90. • Wong, K. et al., 1994. Acute oxalatenephropathy after a massive intravenous dose of vitamin C. Aust ZN J Med, Volume 24, pp. 410-1. • Yeom, C., Jung, G. & Song, K., 2007. Changes of terminal cancer patietnshealthrelatedqualtiy of life after high dose vitamin C administration. Korean Med Sci, Volume 22, pp. 7-11. • Yeom, C. et al., 2009. High-dose concentrationadministration of ascorbic acid inhibits tumor growth in BALB/C miceimplantedwithsarcoma 180 cancer cells via therestriction of angiogenesis. J Transl Med, Volume 7, p. 70. • REFERENCES • Agus, D., Vera, J. & Golde, D., 1999. Stromalcelloxidation: a mechanism by which tumors obtain vitamin C. Cancer Res., Volume 59, pp. 4555-8. • Ashino, H. et al., 2003. Novelfunction of ascorbic acid as an angiostaticfactor. Angiogenesis, Volume 6, pp. 259-69. • Belin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associatedwithinhibition of genes necessary to cellcycleprogression. PLoS ONE, Volume 4, p. e4409. • Benade, L., Howard, T. & Burk, D., 1969. Synergistic killing of Ehrlichascitescarcinomacells by ascorbate and 3-amino-1,2,4-triazole. Oncology, Volume 23, pp. 33-43. • Berlin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associatedwithinhibition of genes necessary for cellcycleprogression. PLoS ONE, Volume 4, pp. E44-0. • Block, K. et al., 2008. Impact of antioxidantsupplementaiononchemotherapeutic toxicity: a systematicreview of theevidence from randomizedcontrolled trials. Int J Cancer, Volume 123, pp. 1227-39. • Cameron, E. & Pauling, L., 1976. Supplemental ascorbate in thesupportive treatment of cancer: Prolongation of survival times in terminal human cancer. PNAS USA, Volume 73, pp. 3685-9. • Cameron, E., Pauling, L. & Leibovitz, B., 1979. Ascorbic acid and cancer, a review. Cancer Res, Volume 39, pp. 663-81. • Campbell, A. & Jack, T., 1979. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J, Volume 24, p. 151. • Campbell, G., Steinberg, M. & Bower, J., 1975. Letter: ascorbic acid inducedhemolysis in a G-6-PD deficiency.. Ann Intern Med, Volume 82, p. 810. • Casciari, J., Riordan, H., Miranda-Massari, J. & Gonzalez, M., 2005. Effects of high dose of ascorbateadministrationon L-10 tumor growth in guineapigs. PRHSJ, Volume 24, pp. 145-50. • Casciari, J., Riordan, N. S. T. M. X., Jackson, J. & Riordan, H., 2001. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitrotumours. Br. J. Cancer, Volume 84, pp. 1544-50. • Chen, Q. et al., 2008. Pharmaologic doses of ascorbateact as a prooxidant and decreasegrowth of aggressive tumor xenografts in mice. PNAS USA, Volume 105, pp. 11105-9. • Chen, Q. et al., 2005. Pharmacologicascorbic acid concentrationsselectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS USA, Volume 205, pp. 13604-13609. • Creagan, E. et al., 1979. Failure of high-dose vitamin C (ascorbic acid) therapy to benefitpatientswithadvanced cancer: A controlled trial. NEJM, Volume 301, pp. 687-690. • Drisko, J., Chapman, J. & Hunter, V., 2003. The use of antioxidantswith first-line chemotherapy in two cases of ovarian cancer. Am J Coll Nutr, Volume 22, pp. 118-23. • Du, J. et al., 2010. Mechanisms of ascorbate-inducedcytotoxicity in pancreatic cancer. Clin Cancer Res, Volume 16, pp. 509-20. • Espey, M. et al., 2011. Pharmacologicascorbatesynergizeswithgemcitabine in preclinicalmodels of pancreatic cancer. Free RadicBiol Med, Volume 50, pp. 1610-19. • Espey, M., Chen, Q. & Levine, M., 2009. Comment re: vitamin C antagonizesthecytotoxiceffects of chemotherapy. Cancer Research , Volume 69, p. 8830. • Frei, B. & Lawson, S., 2008. Vitamin C and cancer revisited. PNAC USA, Volume 105, pp. 11037-8. • Fromberg, A. et al., 2011. Ascorbateexerts anti-proliferativeeffectsthroughcellcycleinhibition and sensitizes tumor cellstowardcytostaticdrugs.. Cancer ChemotherPharmacol, Volume 67, pp. 1157-66. • Fujita, K. et al., 1982. Reduction of adriamycin toxicity by ascorbate in mice and guineapigs. Cancer Res, Volume 309-16, p. 42. • Geeraert, L., 2012. CAM-Cancer Consortium. Intravenoushigh-dose vitamin C. [Online] • Available at: http://www.cam-cancer.ort/CAM-Summaries/Other-CAM/Intravenous-high-dose-vitamin-C. • Ginter, E., Bobeck, P. & Vargova, D., 1979. Tissue levels and optimal dosage of vitamin C in guineapigs.. NutrMetab, Volume 27, pp. 217-26. • Gonzalez, M. et al., 2002. Inhibition of human breast cancer carcinomacellproliferation by ascorbate and copper.. PRHSJ, Volume 21, pp. 21-3.Heaney, M. et al., 2008. Vitamin C antagonizesthecytotoxiceffects of antineoplasticdrugs. Cancer Res., Volume 68, pp. 8031-8. • Henson, D., Block, G. & Levine, M., 1991. Ascorbic acid: biologicalfunctions and relation to cancer. JNCI, Volume 83, pp. 547-50. • Hoffer, L. et al., 208. Phase I clinical trial of i.v. ascorbic acid in advancedmalignancy. Ann Oncol, Volume 1969-74, p. 19. • Hoffman, F., 1985. Micronutrientrequirements of cancer patients.. Cancer, 55(Supl. 1), pp. 145-50. • Hornig, D., 1975. Distribution of ascorbic acid metabolites and analogues in man and animals. Ann NY AcadSci, Volume 258, pp. 103-18. • Jackson, J. & Hunninghake, R., 2006. False positive bloodglucosereadings after high-dose intravenous vitamin C. J Ortho Med, Volume 21, pp. 188-90. • Jackson, J., Riordan, H., Hunninghauke, R. & Riordan, N., 1995. High dose intravenous vitamin C and long time survival of a patient with cancer of the head and pancreas. J Ortho Med, Volume 10, pp. 87-8. • Keith, M. & Pelletier, O., 1974. Ascorbic acid concentrations in leukocytes and selected organs of guineapigs in response to increasingascorbic acid intake. Am J ClinNutr, Volume 27, pp. 368-72. • Kuether, C., Telford, I. & Roe, J., 1988. The relation of thebloodlevel of ascorbic acid to tissue concentrations of this vitamin and thehistology of theincisorteeth in theguineapig. J Nutrition, Volume 28, pp. 347-58. • Kurbacher, C. et al., 1996. Ascorbic acid (vitamin C) improvestheantineoplasticactivity of doxorubicin, cisplatin, and paclitaxel in human breastcarcinomacells in vitro. Cancer Lett, Volume 103, pp. 183-9. • Levine, M. et al., 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommendeddietaryallowance. PNAS USA, Volume 93, pp. 3704-9. • Lin, A., Chen, K., Chung, H. & Chang, S., 2010. The significance of plasma c-reactive protein in patientswithelevated serum prostate-specific antigen levels. UrologicalSci, Volume 21, pp. 88-92.

  11. De mest vanlige IV Cocktails • Meyer’s/Myers’ Cocktail • Mineral og vitamin blanding brukt for ME, tretthet, fibromyalgi, depresjon, muskel spasmer, astma, allergier/utslett, CHF/hjertesvikt (veldig sakte drypp!), angina, infeksjoner, og demens. Brukt for å forhindre forkjølelse og influensa, styrke immunforsvaret og øke energi. • Liver Detoxification – • glutathione, alphalipoic acid, hepar compositum and high dose vitamin C • Dr. Gallagher’s Cocktail – • Øke energi, forbedre enzym funksjoner og nerve funksjoner • vitamin c, glutathione, glyoxal compositum • Heart Health • magnesium, sporstoffer, cerecomp, vitaminer • Migraine • magnesium, riboflavin – kan gis som et push • HangoverRecovery Accelerator • Saline (0.9% NaCl), B vitaminer, vitamin C and glutathione.

  12. Myers’ Cocktail • Utviklet av John Myers, MD • Begynte i 1954 • John Hopkins sykehus, Maryland • Alan Gaby, MD, treated thousands of patients with the Myers’ Cocktail over many years

  13. Fibromyalgi – smerte behandling • 2 cc MgSO4 50% IV pushes: • Føles som om man blir fryktelig varm og tisser på seg …. • Traumeel – homeopatisk traume medisin i sterile ampuller • Methylkobalamin – hjelper ofte på energien

  14. Enzymer og HCl Betaine Fordøyelsen: • HCl Betaine (400-800 mg/tab) • Din dose? Øk med 1 til brenning i magen • Først beskytt slimhinnen i magesekken • Lipase • For bruk av fordøyelse av fett /GB problematikk • Pepsin, trypsin, amylase, cellulase, protease, sukralase, laktase.….. • Super DigestAway– inneholder glutamin • Superzym • DPP IV • Bryter ned gluten og kasein • DPP IV inhibitors/Gliptins: DM2 • Wobenzyme (4-8 tab x 3-4/d akutt) • Betennelse og smerter, ledd problemer • Tysk produsert • Serrapeptase • Betennelse, smerter, etter kirurgi/traumer, blodpropper • Nattokinase • Blodpropper (bryter ned fibrinogen), CVD, kronisk bihulebetennelse, øker HDL • Super oxidedismutase (SOD) • Autoimmun reaksjoner PMID: 29896077 • Alzheimers, Parkinson • DiamineOxidase (DAO) • Histamin intolerance (HIT) syndromet

  15. . Kilder "The story behindWobenzym". Wobenzym.com. Retrieved 2016-04-12. "Science". Wobenzym.com. Retrieved 2016-04-12 Mazzone A, Catalani M, Costanzo M, et al. Evaluation of Serratiapeptidase in acute or chronic inflammation of otorhinolaryngologypathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res 1990;18:379-88.. Viewabstract. Nakamura S, Hashimoto Y, Mikami M, et al. Effect of theproteolyticenzymeserrapeptase in patientswithchronicairway disease. Respirology 2003;8:316-20.. Viewabstract. Shimizu H, Ueda M, Takai T, et al. A case of serratiopeptidase-inducedsubepidermalbullousdermatosis. J Int Med Res 1990;18:379-88.. Viewabstract. Tachibana M, Mizukoshi O, Harada Y, et al. A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomybuccalswelling. Pharmatherapeutica 1984;3:526-30.. Viewabstract. https://www.sciencedirect.com/topics/neuroscience/superoxide-dismutase AllergolInt. October 2017; 66 (4), 594-602 Doctor Murray 2018 IntegrBlood Press Control. 2016 October 13; 9: 95–104 Int J Mol Sci. Acta Haematol. 1990;84(3):139-43 BiolPharm Bull 1995 September;18(9):1194-6 Life Extension December 2016 Life Sci. 2003 July 25;73(10):1289-98 NutrRes. 2009 March;29(3):190-6 Angiology. 2003 September-October;54(5):531-9 Experimentia. 1987 October 15;43(10):1110-1 BioskiBiotechnolBiochem. 2013;77(2):392-4 Smart Publications Nattokinase — The Natural Blood Thinner The Baseline of Health Foundation 1999-2017 HumExpToxicol. 2013 July;32(7):721-35

  16. Kjertelmedisin • 1925 textbook Medical Glandular Therapy was published as a joint project between the American Medical Association and the University of Chicago • Glandular Physiology and Therapy: Prepared Under the Auspices of the Council on Pharmacy and Chemistry of the American Medical Association • Astwood, E B et al 1955 • Aktive ingredienser: • Hormoner, enzymer • Næringsrik • Vitaminer, mineraler, aminosyrer, fettsyrer, DNA/RNA, polypeptider….. • Adaptogenisk effekt • Polypeptider påvirker hormoner • PMID: 22347152 • Sparer egne kjertler • (Hans Selye)

  17. Stoffskifte - kjertelmedisin Blod test: fT3, fT4, TSH, anti TPO, anti TG, rT3 • Armour • Erfa • Naturethroid • Westhroid • WP Thyroid • Thyrolar • Compounded thyroid: • Apoteket lager blanding av T2, T3 og T4 spesifisert til pasientens behov

  18. Binyre kjertelmedisin Test: Spytte test x 4 + 24 timers urin • Adrenal Cortex • Adrenal glandulars • Adrenal health • Adrenavive • Adrenal _______

  19. Pankreas/Bukspyttkjertel kjertelmedisin • Pankreas • Diabetes – spesielt type 1 • Tidligere histore av pankreatisk sykdommer • Cystisk fibrose • Redusert pankreas funksjon • Kreft

  20. Lever/GB kjertelmedisin • Ox bile (galle fra okse), Lipase • De som har fjernet GB • Får diare med feit mat • Lys avføring • Kvalm etter måltider • Tørr hud (lite opptak av fett)

  21. Mild depresjon/Lavt stoffskifte/kroniske smerter • Tarmhelse- probiotika!! • Tester for nevrotransmittere i 24 timers urin • Mest vanlig mangler: • Dopamin: lite tiltak/lite energi/sitter fast i sofaen -Tyrosin • Serotonin: gråter mye, trist, søvn - 5HTP, Inositol • Gamma-aminobutyric acid; uro/angst, søvnforstyrrelser – GABA, Inositol? • Acetylcholine; lærevansker, hukommelse, mentalt trøtt, Alzheimers, demens, Parkinsons PMID: 23202919 • S-Adenosyl L-methionine (SAM-e) • Antidepressive effekt/smertelindring PMID: 28682528

  22. Kilder • References: • Alzheimer’s disease medicationfactsheet. (n.d.). National InstituteonAging. Retrieved from http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-medications-fact-sheet • American Psychological Association. APA Concise Dictionary of Psychology. Washington, DC: American Psychological Association, 2009. Print. • Background to Parkinson’s Disease. (n.d.). Brown UniversityDivision of Biology and Medicine. Retrieved from http://biomed.brown.edu/Courses/BI108/BI108_1999_Groups/Neuroelectrodes_Team/background.html • Colman, A. M. (2006). Oxford Dictionary of Psychology. New York, NY: Oxford University Press. References • Tiwari, Prashant; Dwivedi, Shubhangi; Singh, MukeshPratap; Mishra, Rahul; Chandy, Anish (2017-05-15). "Basic and modernconceptsoncholinergicreceptor: A review". Asian Pacific Journal of Tropical Disease. 3 (5): 413–420. doi:10.1016/S2222-1808(13)60094-8. ISSN 2222-1808. PMC 4027320. • BaigAM, Rana Z, Tariq S, Lalani S, Ahmad HR (March 2018). "TracedontheTimeline: Discovery of Acetylcholine and the Components of the Human Cholinergic System in a Primitive Unicellular Eukaryote Acanthamoebaspp". ACS ChemNeurosci. 9 (3): 494–504. doi:10.1021/acschemneuro.7b00254. PMID 29058403. • BaigAM, Ahmad HR (June 2017). "Evidence of a M1-muscarinic GPCR homolog in unicellular eukaryotes: featuringAcanthamoebasppbioinformatics 3D-modelling and experimentations". J. Recept. Signal Transduct. Res. 37 (3): 267–275. doi:10.1080/10799893.2016.1217884. PMID 27601178. • SmythiesJ (2009). "Philosophy, perception, and neuroscience". Perception. 38 (5): 638–51. doi:10.1068/p6025. PMID 19662940. • SmythiesJ, d'Oreye de Lantremange M (2016). "The Nature and Function of Digital Information CompressionMechanisms in the Brain and in Digital Television Technology". Front SystNeurosci. 10: 40. doi:10.3389/fnsys.2016.00040. PMC 4858531. PMID 27199688. • Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL, eds. (2009-01-01). Miller'sAnesthesia (7th ed.). Elsevier Health Sciences. pp. 343–47. ISBN 0-443-06959-X. • Kellogg DL, Zhao JL, Coey U, Green JV (February 2005). "Acetylcholine-inducedvasodilation is mediated by nitricoxide and prostaglandins in human skin". J. Appl. Physiol. 98 (2): 629–32. doi:10.1152/japplphysiol.00728.2004. PMID 15649880. • Jones BE (November 2005). "From waking to sleeping: neuronal and chemicalsubstrates". Trends Pharmacol. Sci. 26 (11): 578–86. doi:10.1016/j.tips.2005.09.009. PMID 16183137. • HimmelheberAM, Sarter M, Bruno JP (June 2000). "Increases in corticalacetylcholinerelease during sustainedattentionperformance in rats". Brain Res Cogn Brain Res. 9 (3): 313–25. doi:10.1016/S0926-6410(00)00012-4. PMID 10808142. • Ridley RM, Bowes PM, Baker HF, Crow TJ (1984). "An involvement of acetylcholine in objectdiscriminationlearning and memory in themarmoset". Neuropsychologia. 22 (3): 253–63. doi:10.1016/0028-3932(84)90073-3. PMID 6431311. • Francis PT, Palmer AM, Snape M, Wilcock GK (February 1999). "The cholinergichypothesis of Alzheimer's disease: a review of progress". J. Neurol. Neurosurg. Psychiatry. 66 (2): 137–47. doi:10.1136/jnnp.66.2.137. PMC 1736202. PMID 10071091. • Platt B, Riedel G (August 2011). "The cholinergic system, EEG and sleep". Behav. Brain Res. 221 (2): 499–504. doi:10.1016/j.bbr.2011.01.017. PMID 21238497. • Woolf NJ, Butcher LL (May 1986). "Cholinergic systems in the rat brain: III. Projections from thepontomesencephalictegmentum to the thalamus, tectum, basal ganglia, and basal forebrain". Brain Res. Bull. 16 (5): 603–37. doi:10.1016/0361-9230(86)90134-6. PMID 3742247. • Woolf NJ, Butcher LL (December 1989). "Cholinergic systems in the rat brain: IV. Descendingprojections of thepontomesencephalictegmentum". Brain Res. Bull. 23 (6): 519–40. doi:10.1016/0361-9230(89)90197-4. PMID 2611694. • GoldbergJA, Reynolds JN (December 2011). "Spontaneous firing and evoked pauses in thetonicallyactivecholinergicinterneurons of thestriatum". Neuroscience. 198: 27–43. doi:10.1016/j.neuroscience.2011.08.067. PMID 21925242. • Morris G, Arkadir D, Nevet A, Vaadia E, Bergman H (July 2004). "Coincident but distinctmessages of midbraindopamine and striatal tonicallyactive neurons". Neuron. 43 (1): 133–43. doi:10.1016/j.neuron.2004.06.012. PMID 15233923. • CrowTJ, Grove-White IG (October 1973). "An analysis of thelearning deficit followinghyoscineadministration to man". Br. J. Pharmacol. 49 (2): 322–7. doi:10.1111/j.1476-5381.1973.tb08379.x. PMC 1776392. PMID 4793334. • Ridley RM, Murray TK, Johnson JA, Baker HF (June 1986). "Learning impairmentfollowinglesion of the basal nucleus of Meynert in themarmoset: modification by cholinergicdrugs". Brain Res. 376 (1): 108–16. doi:10.1016/0006-8993(86)90904-2. PMID 3087582. • EastonA, Ridley RM, Baker HF, Gaffan D (July 2002). "Unilateral lesions of thecholinergic basal forebrain and fornix in onehemisphere and inferior temporal cortex in theoppositehemisphereproduce severe learningimpairments in rhesusmonkeys". Cereb. Cortex. 12 (7): 729–36. doi:10.1093/cercor/12.7.729. PMID 12050084. • Dean B (November 2009). "Evolution of the human CNS cholineric system: has thisresulted in theemergence of psychiatric disease?". Aust N Z J Psychiatry. 43 (11): 1016–28. doi:10.3109/00048670903270431. PMID 20001397.

  23. Sex Hormoner

  24. DHEA- dehydroepiandrosterone • Teste binyrebark funksjonen • Overlevelseshormonet • Kvinner: 5-10 mg • Libido • Menn: 25-50 mg • Kan øke testosteron (+ Sink og MACA) • 7-keto DHEA 100-200 mg • Øker forbrenningen litt – ca 100 kalorier ekstra om dagen • Ingen effekt på sex hormonene (Likevel på WADA listen)

  25. Progesteron • Blod eller spytte test • Skal ha en referanse verdi • Forholdet til østrogen er viktig • I USA solgt som tilskudd fordi de aller fleste er østrogen dominante • Wild Yam

  26. Østrone/Østradiol/Østriol (E1, E2, E3) • Test: Blodprøve eller spytteprøve • Østrogen må være i balanse med progesteron • Må også være i balanse seg i mellom – EQ • Kan være med på å balanser autoimmun reaksjoner • Henry Lemon, MD – 40 års forskning på risiko for brystkreft • Jonathan Wright, MD, Seattle • Bio Identicalhormonespecialist • Reduser østrogen med: • DIM, I3C, Linfrø/Fiber….. • calcium-D-glucarate, milk thistle, choline, and taurine….

  27. Behandlingsdoser av tilskudd tilgjengelig i Norge • N-acetyl cysteine: • 900 mg hver 3. time for forkjølelse/slim til tarm toleranse • 900 mg daglig for KOLS, astma, slim i lunger/tarmer, lever problemer/detox, røykere • Magnesium: Daglig 900-1200 mg • Ved mangler: • 400-600 mg hver 3. time til tarm toleranse • Formen på magnesium viktig: • Carbonate, oxid, hydroxid, malate,lactate, citrate, orotate, chelate, bisglycate, taurate • Malate – ME/Fibromyalgi • PMID: 25170357 • Vitamin C: Daglig 1-3 gram • Ved forkjølelse/influensa: • 3 gram hver 3. time til tarm toleranse • Vitamin D: Daglig 2000-3000 IU • Ved sykdom: 5-10000 IU hver 3. time • Ved mangler: • 10 000 IU daglig – test etter 1 måned • 50 000 IU IM + 5000 IU daglig – test etter 3 uker Til tarm toleranse – TTT: Til du får diare

  28. Noen urter som jeg brukte i USA – restriksjoner på i Norge • Boswellia (Indisk frankincense) • Scutallerialateriflora – Praktskjoldbærer • Thujaoccidentalis • Piper methysticum /Kava Kava • Valarianaspp. • Eschscholziacalifornica/Kalifornia valmue/morfin • Ashwaganda/Indisk ginseng • HolyBasil (Tulsi)/Hellig basilikum • Ammivisnaga (Tannstikke) • Raowolfiaserpentina /Raovulfia/Indisk slangerot • Hawthorn/Crataegus/Hagtorn • Carditon – Ayush Herbs • Blodtrykkssenkende

  29. Takk for oppmerksomheten! • Oddveig Myhre • Tlf: 95 48 02 38 • oddveig@velkommentiloss.no • Facebook: • Dr. Oddveig Myhre • Optimalhelse Senter Skien – OSS • www.velkommentiloss.no

More Related